Canadian biotech stocks suffer as bad news mounts
Canada's National Post chronicles some tough times in the country's biotech sector. Former high-flyers like QLT and Angiotech have seen their stocks come back to earth after rocketing up. And this year the sector has done much worse in comparison to the much bigger biotech industry to the south. Insiders lament that biotech is tough, with a long, hard road to travel from proof of concept to a marketable product. It's not all bad news, though. Theratechnologies has done well this year.
- read the article from the National Post
Related Articles:
Canada readies efforts to curtail drug traffic. Report
QLT delays clinical program on Atrigel. Report
QLT slashes spending as competition looms. Report
Angiotech to acquire AMI in $785M buyout. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets